Dr. Alejandra Gonzalez-Duarte, MD

National Institute of Medical Sciences and Nutrition–Salvador Zubiran, Mexico

Talk Title: Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis

A.Gonzalez‑Duarte¹, D. Adams², W.D. O’Riordan³, C.-C. Yang⁴, M. Ueda⁵, A.V. Kristen⁶, I. Tournev⁷, H.H. Schmidt⁸, T. Coelho⁹, J.L. Berk¹⁰, K.-P. Lin¹¹, G. Vita¹², S. Attarian¹³, V. Plante‑Bordeneuve¹⁴, M.M. Mezei¹⁵, J.M. Campistol¹⁶, J. Buades¹⁷, T.H. Brannagan III¹⁸, B..J. Kim¹⁹, J. Oh²⁰, Y. Parman²¹, Y. Sekijima²², P.N. Hawkins²³, S.D. Solomon²⁴, M. Polydefkis²⁵, P.J. Dyck²⁶, P.J. Gandhi²⁷, S. Goyal²⁷, J. Chen²⁷, A.L. Strahs²⁷, S.V. Nochur²⁷, M.T. Sweetser²⁷, P.P. Garg²⁷, A.K. Vaishnaw²⁷, J.A. Gollob²⁷, and O.B. Suhr²⁸

¹National Institute of Medical Sciences and Nutrition–Salvador Zubiran, Mexico City; ²Assistance Publique–Hopitaux de Paris (APHP), National Reference Center for Familial Amyloidotic Polyneuropathy, Centre HospitalierUniversitaire (CHU) Bicetre, INSERM Unite 1195, Universite Paris-Sud, Le Kremlin-Bicetre, France; ³Department of Clinical Research, eStudySite, San Diego, CA; ⁴the Department of Neurology, National Taiwan University Hospital, Taiwan; ⁵Kumamoto University Hospital, Kumamoto , Japan; ⁶the Department of Cardiology, University of Heidelberg, Heidelberg, Germany; ⁷University Multiprofile Hospital for Active Treatment, Sofia, Bulgaria; ⁸Medizinische Klinik B fur Gastroenterologie und Hepatologie, Universitatsklinikum Munster, Munster, Germany; ⁹Hospital de Santo Antonio, Centro Hospitalar do Porto, Porto, Portugal; ¹⁰the Amyloidosis Center, Department of Medicine, Boston Medical Center, Boston, MA; ¹¹the Department of Neurology, Taipei Veterans General Hospital, Taipei, Taiwan; ¹²the Department of Clinical and Experimental Medicine, University Hospital of Messina, Messina, Italy; ¹³the Department of Neuromuscular Disorders and ALS, Hopital de la Timone, Marseille, France;¹⁴the Department of Neurology, Amyloid Network, CHU Henri Mondor–APHP, Creteil, France; ¹⁵the Departments of Neurology and Medicine, Vancouver General Hospital, Vancouver, BC, Canada; ¹⁶the Department of Nephrology, Hospital Clinic, Barcelona, Spain; ¹⁷the Balearic Islands Health Research Institute and Hospital Son Llatzer, Palma de Mallorca, Spain; ¹⁸the Department of Neurology, Columbia University, College of Physicians and Surgeons, New York; ¹⁹Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea; ²⁰the Department of Neurology, Konkuk University Medical Center, Seoul, South Korea; ²¹the Department of Neurology, Istanbul University, Istanbul, Turkey; ²²Department of Medicine (Neurology and Rheumatology), Shinshu University School of Medicine, Matsumoto, Japan; ²³the Division of Medicine, University College London, London; ²⁴Harvard Medical School, Boston, MA; ²⁵Johns Hopkins Bayview Medical Center, Baltimore; ²⁶the Department of Neurology, Mayo Clinic, Rochester, MN; ²⁷Alnylam Pharmaceuticals, Cambridge, MA; ²⁸and the Department of Public Health and Clinical Medicine, Umea University, Umea, Sweden.

Presenter at the meeting:

Alejandra Gonzalez-Duarte, MD, National Institute of Medical Sciences and Nutrition–Salvador Zubiran, Mexico

Biography: Dr. González-Duarte is a Neurologist and Internist at Instituto Nacional de CienciasMédicas y Nutrición in Mexico City. She is Director of the Autonomic and Small Fiber Laboratory and coordinates a large cohort of patients with Amyloidosis.